Budesonide

Budesonide

SCHEMBL19635

CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NR3C1

The experimentally established mechanism targets of Budesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 known ✓ P04150 13/20 1.00
PGR P06401 7/20 1.00
CYP3A4 P08684 3/20 1.00
HIF1A Q16665 2/20 1.00
CYP2C9 P11712 2/20 1.00
ABCC3 O15438 1/20 1.00
ABCC4 O15439 1/20 1.00
ABCB11 O95342 1/20 1.00
IL5 P05113 1/20 1.00
NR3C2 P08235 1/20 1.00
AR P10275 1/20 1.00
CHRM1 P11229 1/20 1.00
MMP9 P14780 1/20 1.00
NFKB1 P19838 1/20 1.00
THPO P40225 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
HSD17B10 Q99714 1/20 1.00
LMNA P02545 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Budesonide SCHEMBL16139563 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9
Budesonide SCHEMBL17168987 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9
Budesonide SCHEMBL9763339 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9
Budesonide SCHEMBL12440030 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9
Budesonide SCHEMBL10020756 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9
Budesonide SCHEMBL17151422 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9
Budesonide SCHEMBL17971368 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9
Budesonide SCHEMBL13918824 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9
Budesonide SCHEMBL21570019 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9
Budesonide SCHEMBL10051995 1.00 NR3C1 (1.00) NR3C1PGRCYP3A4HIF1ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 6841 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260139860-A1 PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS CENTRE FOR DIGESTIVE DISEASES (AU) 2026-05-21 US claimed
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
EP-4673157-A2 COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME Persephone Biosciences, Inc. (US) 2026-01-07 EP claimed
WO-2025264805-A2 SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME PERSEPHONE BIOSCIENCES, INC. (US) 2025-12-26 WO claimed
US-20250375441-A1 ONCOLYTIC THERAPY WITH A DUAL HDAC3 AND HDAC8 TARGETING AGENT UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2025-12-11 US claimed
EP-3699174-B1 COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME ILAB (KR) 2025-11-12 EP claimed
US-20250269005-A1 METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT TOPELIA AUST LIMITED (ACN 652 771 670) (AU) 2025-08-28 US claimed
US-20250242092-A1 SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS SIO2 MEDICAL PRODUCTS INC (US) 2025-07-31 US claimed
WO-2025151851-A1 BIOMARKERS OF ALLERGIC ASTHMA AND METHODS OF TREATMENT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2025-07-17 WO claimed
WO-2025122610-A1 THERAPEUTIC COMBINATIONS AND METHODS FOR 5-HT3 RECEPTOR MODULATORS IN TREATING VARIOUS DISORDERS SEROTONIX LLC (US) 2025-06-12 WO claimed
US-20040234499-A1 Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses CENTOCOR, INC. 2004-11-25 US claimed
US-20030235555-A1 Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses CENTOCOR, INC. 2003-12-25 US claimed
US-20030236298-A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders ATHEROGENICS PHARMACEUTICALS, INC. 2003-12-25 US claimed
WO-2003086451-A1 ASTHMA-RELATED ANTI-IL-13 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES CENTOCOR, INC. (US) 2003-10-23 WO claimed
US-6608101-B1 Inflammatory disorders; 3-(2,4-dimethoxy-5-(thien-2-yl)phenyl)-1-(4-carboxymethoxy-3,5 -dimethoxyphenyl)-2-propen-1-one; ATHEROGENICS, INC. 2003-08-19 US claimed
US-20030077316-A1 Psoriasis patch AXOGEN CORPORATION 2003-04-24 US claimed
US-20020192273-A1 Therapeutic patch useful for the treatment of hemorrhoids LEC TEC CORPORATION 2002-12-19 US claimed
WO-2001041746-A1 ANTI ITCH PATCH LECTEC CORPORATION (US) 2001-06-14 WO claimed
US-6187756-B1 Composition and methods for treatment of neurological disorders and neurodegenerative diseases THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2001-02-13 US claimed
EP-0494942-B1 PROCESS FOR THE MANUFACTURE OF BUDESONIDE ASTRA AB (SE) 1995-11-15 EP claimed